Study Evaluating Safety and Efficacy of Tigecycline Versus Imipenem/Cilastatin Subjects With Hospital-Acquired Pneumonia

NCT00707239

Last updated date
Study Location
Pfizer Investigational Site
Louisville, Kentucky, , United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Bacterial Pneumonia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Male or female subjects, greater than or equal to 18 years of age, known or suspected to have acute hospital-acquired pneumonia (HAP).

- Acute HAP is defined as pneumonia with onset of symptoms:

1. Greater than or equal to 48 hours after admission to an acute care hospital or chronic care facility such as a skilled nursing home facility or rehabilitation unit. Or

2. Less than or equal to 7 days after the subject was discharged from the hospital. The initial hospitalization must have been greater than or equal to 3 days duration.

- VAP is defined as: onset of symptoms of pneumonia greater than or equal to 48 hours after endotracheal intubation.

- Presence of a new or evolving infiltrate on a chest x-ray film, presence of fever or leukocytosis, respiratory failure requiring mechanical ventilation or presence of 2 of the following clinical signs and symptoms: cough, dyspnea or tachypnea, pleuritic chest pain, rales and/or evidence of pulmonary consolidation, hypoxemia, or purulent sputum production.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Subjects with other significant underlying conditions that would make it difficult to
evaluate the subjects or make it unlikely to complete the therapy or that would
increase their risk by participating in the study, infection with organisms known to
be resistant, contraindication, or hypersensitivity to any of the test articles.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Bacterial PneumoniaThe Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP) NCT01189487
  1. Seto-shi, Aichi-ken
  2. Kitakyushu, Fukuoka
  3. Kitakyushu, Fukuoka
  4. Yanagawa, Fukuoka
  5. Asahikawa, Hokkaido
  6. Sapporo, Hokkaido
  7. Himejishi, Hyogo
  8. Takamatsu, Kagawa
  9. Kawasaki-city, Kanagawa
  10. Yokohama, Kanagawa
  11. Koushi-shi, Kumamoto
  12. Shiogama, Miyagi
  13. Matsumoto, Nagano
  14. Isahaya, Nagasaki
  15. Nagasaki-city, Nagasaki
  16. Tsukubo-gun, Okayama
  17. Ureshino-shi, Saga
  18. Sayama, Saitama
  19. Hamamatsu, Shizuoka
  20. Fukuoka,
  21. Kochi,
  22. Kumamoto,
ALL GENDERS
16 Years+
years
MULTIPLE SITES
Bacterial PneumoniaA Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization NCT00797108
  1. Chula Vista, California
  2. Chula Vista, California
  3. Oceanside, California
  4. Oceanside, California
  5. Moline, Illinois
  6. Rock Island, Illinois
  7. Minneapolis, Minnesota
  8. Akron, Ohio
  9. Akron, Ohio
  10. Akron, Ohio
  11. Provo, Utah
  12. Provo, Utah
  13. Brisbane, Queensland
  14. Hamilton, Ontario
  15. Hamilton, Ontario
  16. Hamilton, Ontario
  17. Seoul,
  18. Bialystok,
  19. Brzesko,
  20. Krakow,
  21. Lodz,
  22. Poznan,
  23. Proszowice,
  24. Warszawa,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Bacterial PneumoniaStudy Evaluating Safety and Efficacy of Tigecycline Versus Imipenem/Cilastatin Subjects With Hospital-Acquired Pneumonia NCT00707239
  1. Louisville, Kentucky
  2. Omaha, Nebraska
  3. Morgantown, West Virginia
  4. La Plata, Buenos Aires
  5. Godoy Cruz, Mendoza
  6. La Plata, Provincia de Buenos Aires
  7. Provincia de Buenos Aires,
  8. Nambour, Queensland
  9. Victoria,
  10. Belo Horizonte, MG
  11. Porto Alegre, RS
  12. Sao Jose do Rio Preto, SP
  13. Chicoutimi, Quebec
  14. Trois-Rivieres, Quebec
  15. Santiago,
  16. Medellin, Antioquia
  17. Bogota,
  18. Zagreb,
  19. Argenteuil,
  20. Debrecen,
  21. Nyiregyhaza,
  22. Szekesfehervar,
  23. Vac,
  24. Seoul, Korea
  25. Seoul, Korea
  26. Seoul, Korea
  27. Seoul, Korea
  28. Daugavpils,
  29. Riga,
  30. Riga,
  31. Moscow,
  32. Moscow,
  33. Novosibirsk,
  34. St Petersburg,
  35. St Petersburg,
  36. Vsevolozhsk,
  37. Tainan,
  38. Tainan,
  39. Taipei TOC,
  40. Taipei,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Evaluating Safety and Efficacy of Tigecycline Versus Imipenem/Cilastatin Subjects With Hospital-Acquired Pneumonia
Official Title  ICMJE A Phase 2, Multicenter, Randomized, Double-Blind, Comparative Study Of The Safety And Efficacy of 2 Doses Of Tigecycline Versus Imipenem/Cilastatin For The Treatment Of Subjects With Hospital-Acquired Pneumonia
Brief Summary

This study will compare the safety and efficacy of a tigecycline regimen versus an imipenem/cilastatin regimen for the treatment of subjects who are hospitalized with hospital-acquired pneumonia (HAP). At least 70% of enrolled subjects will have ventilator-associated pneumonia (VAP). Two dose levels of tigecycline will be assessed and compared to imipenem/cilastatin in parallel. Subjects will receive intravenous therapy from a minimum of 7 & up to 14 consecutive days, the exact duration will be at the decision of the investigator based on the subject's condition. Additional protocol specified antibiotics may be given to ensure appropriate coverage. A final assessment at test-of-cure (TOC) visit will be done 10 to 21 days after the last day of therapy. The total duration of subject participation will be between 17 and 44 days, including a follow up period of 30 days after the last day of therapy for SAEs.

Subjects will be followed for safety and efficacy. The safety assessment will include: physical examinations, vital signs, assessment of the clinical signs and symptoms of pneumonia, collection of adverse events, 12-lead ECG, collection of samples for hematology, serum chemistries, and coagulation parameters, & a serum or urine pregnancy test before study entry for women of childbearing potential. The clinical and microbiological efficacy will both be evaluated.

Detailed Description The sponsor internal decision has been taken to close the study on 15 of July 2011, due to difficulties in enrollment. This decision was not based on any safety issues.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Pneumonia, Bacterial
Intervention  ICMJE
  • Drug: tigecycline
    An initial intravenous (IV) loading dose of 150 mg of tigecycline, followed by 75 mg of IV tigecycline approximately every 12 hours (q12h), for up to 14 consecutive days. Ceftazidime 2 g IV approximately every 8 hours, an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and vancomycin placebo given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus [MRSA]).
  • Drug: tigecycline
    An initial intravenous (IV) loading dose of 200 mg of tigecycline, followed by 100 mg of IV tigecycline approximately every 12 hours (q12h), for up to 14 consecutive days. Ceftazidime 2 g IV approximately every 8 hours, an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and vancomycin placebo given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus [MRSA]).
  • Drug: imipenem/cilastatin
    Imipenem/cilastatin 1g intravenous (IV) will be administered approximately every 8 hours, for up to 14 consecutive days. In addition vancomycin 15 mg/kg IV approximately every 12 hours (q12h), an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and ceftazidime placebo will be given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus [MRSA]).
Study Arms  ICMJE
  • Experimental: A
    Intervention: Drug: tigecycline
  • Experimental: B
    Intervention: Drug: tigecycline
  • Active Comparator: C
    Intervention: Drug: imipenem/cilastatin
Publications * Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother. 2013 Apr;57(4):1756-62. doi: 10.1128/AAC.01232-12. Epub 2013 Jan 28.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: August 10, 2011)
108
Original Estimated Enrollment  ICMJE
 (submitted: June 27, 2008)
210
Actual Study Completion Date  ICMJE June 2011
Actual Primary Completion Date June 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or female subjects, greater than or equal to 18 years of age, known or suspected to have acute hospital-acquired pneumonia (HAP).
  • Acute HAP is defined as pneumonia with onset of symptoms:

    1. Greater than or equal to 48 hours after admission to an acute care hospital or chronic care facility such as a skilled nursing home facility or rehabilitation unit. Or
    2. Less than or equal to 7 days after the subject was discharged from the hospital. The initial hospitalization must have been greater than or equal to 3 days duration.
  • VAP is defined as: onset of symptoms of pneumonia greater than or equal to 48 hours after endotracheal intubation.
  • Presence of a new or evolving infiltrate on a chest x-ray film, presence of fever or leukocytosis, respiratory failure requiring mechanical ventilation or presence of 2 of the following clinical signs and symptoms: cough, dyspnea or tachypnea, pleuritic chest pain, rales and/or evidence of pulmonary consolidation, hypoxemia, or purulent sputum production.

Exclusion Criteria:

  • Subjects with other significant underlying conditions that would make it difficult to evaluate the subjects or make it unlikely to complete the therapy or that would increase their risk by participating in the study, infection with organisms known to be resistant, contraindication, or hypersensitivity to any of the test articles.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Argentina,   Australia,   Brazil,   Canada,   Chile,   Colombia,   Croatia,   France,   Hungary,   Korea, Republic of,   Latvia,   Russian Federation,   Taiwan,   United States
Removed Location Countries Belarus,   Estonia,   Israel,   Mexico
 
Administrative Information
NCT Number  ICMJE NCT00707239
Other Study ID Numbers  ICMJE 3074K6-2000
B1811004
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP